000			03059cam a2200325 a 4500
003			EG-GiCUC
008			171111s2017 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.23.M.Sc.2017.Mo.R
100	0		_aMona Mohammed Salem
245	1	0	_aRole of multidisciplinary team of breast cancer care in breast cancer unit at Kasr Alainy center of clinical oncology : _bSingle institution study / _cMona Mohammed Salem ; Supervised Lobna Mahmoud Sedky Khalil , Soha Talima , Heba Khafagy
246	1	5	_aدراسة دور فريق العمل متعدد التخصصات بوحدة سرطان الثدى التابعه لمركز قصرالعينى لعلاج الأورام كلية الطب جامعة القاهره فى دعم و تحسين رعاية مرضى سرطان الثدى
260			_aCairo : _bMona Mohammed Salem , _c2017
300			_a81 P. : _bcharts ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Oncology (Clinical)
520			_aSignificant advances in the diagnosis and treatment of breast cancer have been made which increased the complexity of treatment decision-making and reinforced the need for a team approach. In MDT meetings, the core team members of relevant specialties participate to share their knowledge aiming to ensure that all patients receive timely diagnosis and treatment, that patient management is evidence-based, and that there is continuity of care. In this study, we are trying to evaluate the effectiveness of the role of breast cancer MDT in NEMROCK. Approach: This retrospective study was carried out at Kasr Alainy center of clinical oncology (NEMROCK) during the period between January 2011 and December 2015. The study comprises 584 women with breast cancer, 278 patients in the MDT group, while 306 patients in the non-MDT group. The patients{u2019} files were reviewed and extrapolation of data was performed. Results: Patients in both groups were not evenly distributed, more patients in stage III were found in the MDT group, and therefore patients receiving neo-adjuvant therapy. Neo-adjuvant chemotherapy patients in the MDT group were more likely to receive the standard of care regimen (Anthracyclines and Taxanes), and ending up with more patients achieving cCR (30.5% vs. 12% respectively). The difference in time from diagnosis till start of treatment between the MDT and control group was not statistically significant 4.49 weeks vs. 3.72 respectively (P=0.19). Regarding the type of surgery done, more BCS were done in the control group 35% of the surgeries vs. 27.5% in the MDT group, P=0.055
530			_aIssued also as CD
653		4	_aBreast cancer
653		4	_aBreast conservative surgery
653		4	_aMDT
700	0		_aHeba Khafagy , _eSupervisor
700	0		_aLobna Mahmoud Sedky Khalil , _eSupervisor
700	0		_aSoha Talima , _eSupervisor
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c63385 _d63385